Savara Informed That FDA Will Not Take Action on the Molgramostim BLA by the PDUFA Date
11/20/2026
Impact: -65
Healthcare
Savara said the FDA will not meet the November 22, 2026 PDUFA target date for its molgramostim inhalation solution BLA for autoimmune pulmonary alveolar proteinosis. The review remains ongoing, and the FDA has not provided a new action date. Savara said it continues to focus on developing molgramostim for rare respiratory diseases.
AI summary, not financial advice
Share: